Industry Newsmultiple myelomabcmajnjregulatory approval
Johnson & Johnson Receives FDA Approval For Myeloma
|
7.1
Johnson & Johnson on March 5 said the FDA approved TECVAYLI plus DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma after at least one prior therapy, including a proteasome inhibitor and an immunomodulatory agent. Management said the combination could become a second-line standard for about 40% of relapsing patients by targeting BCMA-expressing cells. JPMorgan also raised JNJ's price target to $250 from $225, keeping a Neutral rating.
Scoring Rationale
High clinical and commercial significance with official FDA approval, limited DS relevance outside biotech investing.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
